ICU MED INC's ticker is ICUI and the CUSIP is 44930G107. A total of 215 filers reported holding ICU MED INC in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,512 | -35.1% | 12,708 | -2.9% | 0.01% | -31.6% |
| Q2 2023 | $2,331 | +0.6% | 13,083 | -6.8% | 0.02% | -5.0% |
| Q1 2023 | $2,316 | -7.5% | 14,037 | -11.7% | 0.02% | -9.1% |
| Q4 2022 | $2,505 | -99.9% | 15,905 | +9.3% | 0.02% | +4.8% |
| Q3 2022 | $2,192,000 | -8.1% | 14,554 | +0.3% | 0.02% | -4.5% |
| Q2 2022 | $2,386,000 | -22.3% | 14,515 | +5.3% | 0.02% | -8.3% |
| Q1 2022 | $3,070,000 | -54.8% | 13,787 | -51.8% | 0.02% | -4.0% |
| Q4 2021 | $6,790,000 | +104.7% | 28,612 | +101.3% | 0.02% | -10.7% |
| Q3 2021 | $3,317,000 | +3.6% | 14,211 | -8.7% | 0.03% | +7.7% |
| Q2 2021 | $3,203,000 | +458.0% | 15,566 | +456.7% | 0.03% | +18.2% |
| Q1 2021 | $574,000 | -10.7% | 2,796 | -6.7% | 0.02% | -8.3% |
| Q4 2020 | $643,000 | +17.8% | 2,997 | +0.3% | 0.02% | 0.0% |
| Q3 2020 | $546,000 | -1.8% | 2,987 | -1.0% | 0.02% | -7.7% |
| Q2 2020 | $556,000 | -40.1% | 3,018 | -34.4% | 0.03% | +13.0% |
| Q1 2020 | $928,000 | +5.6% | 4,599 | -2.1% | 0.02% | +43.8% |
| Q4 2019 | $879,000 | +28.3% | 4,700 | +9.4% | 0.02% | +14.3% |
| Q3 2019 | $685,000 | -34.1% | 4,295 | +4.0% | 0.01% | -41.7% |
| Q2 2019 | $1,040,000 | +17.1% | 4,129 | +11.3% | 0.02% | +9.1% |
| Q1 2019 | $888,000 | +5.7% | 3,709 | +1.3% | 0.02% | -8.3% |
| Q4 2018 | $840,000 | +29.6% | 3,660 | +59.6% | 0.02% | +50.0% |
| Q3 2018 | $648,000 | -41.8% | 2,293 | -39.5% | 0.02% | -40.7% |
| Q2 2018 | $1,114,000 | +101.4% | 3,793 | +73.2% | 0.03% | +80.0% |
| Q1 2018 | $553,000 | +16.9% | 2,190 | -0.1% | 0.02% | +15.4% |
| Q4 2017 | $473,000 | +23.8% | 2,192 | +6.8% | 0.01% | +8.3% |
| Q3 2017 | $382,000 | +7.3% | 2,053 | -0.5% | 0.01% | 0.0% |
| Q2 2017 | $356,000 | +19.1% | 2,063 | +5.3% | 0.01% | -20.0% |
| Q1 2017 | $299,000 | +3.1% | 1,959 | -0.4% | 0.02% | +15.4% |
| Q4 2016 | $290,000 | +33.6% | 1,967 | +14.8% | 0.01% | 0.0% |
| Q3 2016 | $217,000 | +1.4% | 1,714 | +0.1% | 0.01% | +8.3% |
| Q2 2016 | $214,000 | – | 1,713 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EVR Research LP | 22,000 | $4,719,000 | 3.86% |
| NUANCE INVESTMENTS, LLC | 901,483 | $193,359,000 | 3.73% |
| Nitorum Capital, L.P. | 417,241 | $89,494,000 | 3.46% |
| Tamarack Advisers, LP | 73,000 | $15,452,000 | 3.22% |
| PFM Health Sciences, LP | 267,817 | $57,444,000 | 2.02% |
| KIRR MARBACH & CO LLC /IN/ | 22,222 | $4,766,000 | 1.49% |
| PURA VIDA INVESTMENTS, LLC | 174,399 | $37,407,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,584 | $554,000 | 0.88% |
| Findlay Park Partners LLP | 528,825 | $113,428,000 | 0.79% |
| Altium Capital Management LP | 9,321 | $1,999,000 | 0.75% |